Latest Period
Q4 2025
Security Snapshot
Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN) Institutional Ownership
CUSIP: 29337E102
13F Institutional Holders and Ownership History from Q1 2023 to Q1 2026
Institutions Reporting
125
Shares (Excl. Options)
62,391,024
Price
$15.40
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- ELVN on Nasdaq
- Shares outstanding
- 58,923,077
- Price per share
- $45.32
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 62,391,024
- Total reported value
- $960,824,930
- % of total 13F portfolios
- 0%
- Share change
- +2,259,081
- Value change
- +$20,216,707
- Number of holders
- 125
- Price from insider filings
- $45.32
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share is tracked under CUSIP 29337E102.
- 125 institutions reported positions in Q4 2025.
- 8 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 125 to 56 between Q4 2025 and Q1 2026.
- Reported value moved from $960,824,930 to $172,638,883.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 125 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 29337E102?
CUSIP 29337E102 identifies ELVN - Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 29337E102:
Significant Owners of Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 13% | $140,468,212 | 7,918,163 | ORBIMED ADVISORS LLC | 16 Jun 2025 | |||
| FMR LLC | 13% | $161,103,383 | 7,870,219 | FMR LLC | 30 Sep 2025 | |||
| Commodore Capital LP | 9.9% | $135,215,385 | 6,022,957 | Commodore Capital LP | 30 Jun 2025 | |||
| Vestal Point Capital, LP | 6.5% | $98,622,500 | 3,830,000 | Vestal Point Capital, LP | 31 Dec 2025 | |||
| Fairmount Funds Management LLC | 6.3% | -4.3% | $83,321,918 | +$11,419,103 | 3,711,444 | +16% | Fairmount Funds Management LLC | 30 Jun 2025 |
| Venrock Healthcare Capital Partners III, L.P. | 5.4% | $66,042,996 | 3,226,331 | Venrock Healthcare Capital Partners III, L.P. | 30 Sep 2025 | |||
| BlackRock, Inc. | 5.1% | $59,005,266 | 2,941,395 | BlackRock, Inc. | 30 Jun 2025 | |||
| Polar Capital Holdings Plc | 5.2% | +5.6% | $56,952,978 | +$3,304,932 | 2,536,881 | +6.2% | Polar Capital Holdings Plc | 30 Jun 2025 |
As of 31 Dec 2025, 125 institutional investors reported holding 62,391,024 shares of Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN). This represents 106% of the company’s total 58,923,077 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN) together control 96% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 14% | 7,959,538 | 0% | 2.6% | $122,576,885 |
| FMR LLC | 12% | 7,107,635 | -0.3% | 0.01% | $109,457,572 |
| Commodore Capital LP | 8% | 4,692,809 | 0% | 4.8% | $72,269,259 |
| Vestal Point Capital, LP | 6.5% | 3,830,000 | +230% | 2.2% | $58,982,000 |
| Fairmount Funds Management LLC | 6.3% | 3,711,444 | 0% | 4.4% | $57,156,238 |
| BlackRock, Inc. | 6.1% | 3,613,326 | +2.7% | 0% | $55,645,219 |
| Polar Capital Holdings Plc | 6% | 3,513,680 | +14% | 0.25% | $54,110,672 |
| VR ADVISER, LLC | 5.5% | 3,226,331 | 0% | 2.5% | $49,685,497 |
| VANGUARD GROUP INC | 4.8% | 2,801,665 | +9.7% | 0% | $43,145,640 |
| JANUS HENDERSON GROUP PLC | 2.8% | 1,671,724 | -6.8% | 0.01% | $25,744,550 |
| Point72 Asset Management, L.P. | 2.6% | 1,504,601 | +45% | 0.04% | $23,170,855 |
| NOVO HOLDINGS A/S | 2.5% | 1,480,000 | +3.8% | 1.8% | $22,792,000 |
| CITADEL ADVISORS LLC | 2.4% | 1,424,344 | +23% | 0.01% | $21,934,897 |
| Capital Research Global Investors | 2.2% | 1,304,346 | -0.85% | 0% | $20,086,928 |
| Pictet Asset Management Holding SA | 2.2% | 1,303,235 | -6.8% | 0.02% | $20,069,819 |
| STATE STREET CORP | 1.8% | 1,052,862 | +9.1% | 0% | $16,214,075 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.8% | 1,048,722 | -3.3% | 0% | $16,153,779 |
| Soleus Capital Management, L.P. | 1.7% | 1,025,000 | 0.67% | $15,785,000 | |
| Blackstone Inc. | 1.6% | 954,946 | -28% | 0.06% | $14,706,168 |
| Rock Springs Capital Management LP | 1.4% | 798,405 | +16% | 0.63% | $12,295,437 |
| 5AM Venture Management, LLC | 1.3% | 772,477 | 0% | 3.7% | $11,896,146 |
| Candriam S.C.A. | 0.77% | 453,019 | -26% | 0.03% | $6,976,790 |
| Spruce Street Capital LP | 0.76% | 446,084 | 0% | 2.3% | $6,869,694 |
| MORGAN STANLEY | 0.7% | 411,823 | +59% | 0% | $6,342,080 |
| DIMENSIONAL FUND ADVISORS LP | 0.68% | 398,893 | +149% | 0% | $6,143,418 |
Institutional Holders of Enliven Therapeutics, Inc. - Common Stock, par value $0.001 per share (ELVN) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 4,405,340 | $172,638,883 | +$50,950,343 | $39.20 | 56 |
| 2025 Q4 | 62,391,024 | $960,824,930 | +$20,216,707 | $15.40 | 125 |
| 2025 Q3 | 59,389,507 | $1,215,687,864 | -$296,366 | $20.47 | 132 |
| 2025 Q2 | 59,434,902 | $1,192,251,085 | +$192,194,924 | $20.06 | 123 |
| 2025 Q1 | 49,886,849 | $983,923,667 | +$4,352,699 | $19.68 | 118 |
| 2024 Q4 | 49,624,914 | $1,116,597,658 | +$24,828,957 | $22.50 | 111 |
| 2024 Q3 | 47,688,348 | $1,218,010,157 | -$20,810,259 | $25.54 | 100 |
| 2024 Q2 | 48,318,843 | $1,129,194,355 | +$91,652,714 | $23.37 | 91 |
| 2024 Q1 | 44,456,336 | $780,753,492 | +$95,045,035 | $17.59 | 72 |
| 2023 Q4 | 39,000,634 | $539,791,932 | -$652,659 | $13.84 | 61 |
| 2023 Q3 | 39,076,502 | $533,779,750 | -$2,178,662 | $13.66 | 60 |
| 2023 Q2 | 39,092,843 | $797,915,923 | +$112,876,379 | $20.41 | 61 |
| 2023 Q1 | 33,557,749 | $734,910,999 | +$734,911,000 | $21.90 | 44 |